The U.S. Food and Drug Administration has approved Galderma's Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback